Wilbur Gantz Net Worth
The estimated Net Worth of Wilbur H Gantz is at least $304 Thousand dollars as of 25 June 2018. Mr. Gantz owns over 23,100 units of Aptinyx stock worth over $265,353 and over the last 16 years he sold APTX stock worth over $0. In addition, he makes $38,244 as Independent Chairman of the Board at Aptinyx.
Mr. Gantz APTX stock SEC Form 4 insider trading
Wilbur has made over 8 trades of the Aptinyx stock since 2007, according to the Form 4 filled with the SEC. Most recently he bought 23,100 units of APTX stock worth $369,600 on 25 June 2018.
The largest trade he’s ever made was buying 39,683 units of Aptinyx stock on 17 October 2017 worth over $50,001. On average, Wilbur trades about 1,105 units every 61 days since 2003. As of 25 June 2018 he still owns at least 80,167 units of Aptinyx stock.
You can see the complete history of Mr. Gantz stock trades at the bottom of the page.
Wilbur Gantz biography
Wilbur H. Gantz III is Independent Chairman of the Board of the Company. Mr. Gantz has served as a member of our board of directors since July 2015. Mr. Gantz has been the President of PathoCapital, an investor in healthcare companies, since March 2009. He previously served as Executive Chairman and Chief Executive Officer of Ovation Pharmaceuticals, Inc., which was sold to Lundbeck, AG in 2009, and as Chairman, Chief Executive Officer and President of PathoGenesis Corporation, a biopharmaceutical company that was sold to Chiron, Inc. in 2000. Prior to founding PathoGenesis, from 1987 to 1992 he served as President of Baxter International, Inc., a manufacturer and marketer of healthcare products. During the past five years, Mr. Gantz has served on the board of directors of Aevi Genomic Medicine, Inc. and W.W. Grainger, Inc. He currently serves on the boards of private companies Harmony Biosciences, LLC, and ReliefBand Technologies LLC. He is a trustee of The Field Museum of Natural History and Brain Research Foundation. Mr. Gantz holds a B.A. degree from Princeton University, where he graduated cum laude, and an M.B.A. from Harvard Business School.
What is the salary of Wilbur Gantz?
As the Independent Chairman of the Board of Aptinyx, the total compensation of Wilbur Gantz at Aptinyx is $38,244. There are 5 executives at Aptinyx getting paid more, with Norbert Riedel having the highest compensation of $1,873,190.
How old is Wilbur Gantz?
Wilbur Gantz is 81, he’s been the Independent Chairman of the Board of Aptinyx since 2015. There are no older and 11 younger executives at Aptinyx.
What’s Wilbur Gantz’s mailing address?
Wilbur’s mailing address filed with the SEC is C/O APTINYX INC., 909 DAVIS STREET, SUITE 600, EVANSTON, IL, 60201.
Insider trading at Aptinyx
Over the last few years, insiders at Aptinyx have traded over $0 worth of Aptinyx stock and bought 2,004,150 units worth $30,473,884 . The most active insider traders include Street Partners Llc Adams, Patrick G Enright, and James N Topper. On average, Aptinyx executives and independent directors trade stock every 15 days with the average trade being worth of $321,970. The most recent stock trade was executed by Henry O Gosebruch on 7 May 2019, trading 100,000 units of APTX stock currently worth $386,000.
What does Aptinyx do?
Aptinyx Inc. is a clinical stage biopharmaceutical company. It engages in the discovery, development, and and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.
Complete history of Mr. Gantz stock trades at Aevi Genomic Medicine, W.W. Grainger, and Aptinyx
Aptinyx executives and stock owners
Aptinyx executives and other stock owners filed with the SEC include:
- Norbert Riedel, President, Chief Executive Officer, Director
- Andrew Kidd, Chief Operating Officer
- Ashish Khanna, Chief Financial Officer, Chief Business Officer
- Joseph Moskal, Chief Scientific Officer
- Robert Hombach, Independent Director
- Wilbur Gantz, Independent Chairman of the Board
- Patrick Enright, Independent Director
- Adam Koppel, Independent Director
- James Topper, Independent Director
- Elisha Gould, Independent Director
- Rachel Sherman, Independent Director
- Henry Gosebruch, Independent Director
- Leaf Venture Management Iii…,
- David Houck, Chief Development Officer
- Torsten M. Madsen, Chief Medical Officer
- Life Sciences Viii, L.P.Fhm…,
- Capital Partners Ii, Llc Ta…,
- Terry P Gould, Director
- Street Partners Llc Adams, 10% owner
- Liam Ratcliffe, Director